Výsledky vyhľadávania - "Janus Kinase Inhibitors adverse effects"

Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials

Autori: Alain Amstutz Stefan Schandelmaier Hannah Ewald a ďalší

Zdroj: The Lancet Respiratory Medicine. 13:530-544

Predmety: Adult, Male, Sulfonamides / therapeutic use, SARS-CoV-2, adult, adverse event, all cause mortality, anemia, Article, artificial ventilation, cardiovascular disease, chronic infection, clinical outcome, coronavirus disease 2019, Cytomegalovirus, digestive system perforation, disease severity, drug effect, drug efficacy, drug safety, hepatitis B, herpes simplex, herpes zoster, high flow nasal cannula therapy, hospital admission, hospitalization, human, immunocompromised patient, liver dysfunction, liver toxicity, lymphocytopenia, meta analysis, mortality, noninvasive ventilation, outcome assessment, oxygen therapy, pancytopenia, quality control, randomized controlled trial (topic), risk assessment, risk factor, sensitivity analysis, Severe acute respiratory syndrome coronavirus 2, systematic review, thrombocytopenia, tuberculosis, viral clearance, virus reactivation, COVID-19 pharmacotherapy, female, male, middle aged, Pyrazoles / therapeutic use, Middle Aged, Azetidines / therapeutic use, COVID-19 Drug Treatment, Hospitalization, COVID-19 / mortality, Piperidines / therapeutic use, Nitriles, Purines / therapeutic use, Pyrimidines / therapeutic use, Humans, Female, Janus Kinase Inhibitors / adverse effects, Janus Kinase Inhibitors / therapeutic use, Randomized Controlled Trials as Topic

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40378861

Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies

Autori: Eric L. Simpson Matthias Augustin Diamant Thaçi a ďalší

Zdroj: Am J Clin Dermatol

Predmety: Pyrazoles/adverse effects [MeSH], Janus Kinase Inhibitors/administration, Pyrazoles/therapeutic use [MeSH], Administration, Cutaneous [MeSH], Male [MeSH], Quality of Life [MeSH], Original Research Article, Pyrimidines [MeSH], Child [MeSH], Dermatitis, Atopic/drug therapy [MeSH], Adolescent [MeSH], Female [MeSH], Adult [MeSH], Humans [MeSH], Skin Cream/administration, Dermatitis, Atopic/diagnosis [MeSH], Severity of Illness Index [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Pyrazoles/administration, Pruritus/etiology [MeSH], Patient Reported Outcome Measures [MeSH], Janus Kinase Inhibitors/adverse effects [MeSH], Nitriles [MeSH], Pruritus/drug therapy [MeSH], Dermatitis, Atopic/complications [MeSH], Young Adult [MeSH]

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39546129
https://repository.publisso.de/resource/frl:6505096

Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis

Autori: Axel Dignass Claire Ainsworth Susanne Hartz a ďalší

Zdroj: Adv Ther

Predmety: Biological Products, Network Meta-Analysis, Remission Induction, Adalimumab, Bayes Theorem, Severity of Illness Index, Treatment Outcome, Gastrointestinal Agents, Humans, Janus Kinase Inhibitors, Colitis, Ulcerative, Colitis, Ulcerative/diagnosis [MeSH], Biologics, IL-23 inhibitors, Humans [MeSH], Severity of Illness Index [MeSH], Treatment Outcome [MeSH], Adalimumab/adverse effects [MeSH], Janus Kinase Inhibitors/administration, Advanced therapies, Bayes Theorem [MeSH], Comparative efficacy, Gastrointestinal Agents/adverse effects [MeSH], Janus Kinase Inhibitors/adverse effects [MeSH], Randomized Controlled Trials as Topic [MeSH], Colitis, Ulcerative/drug therapy [MeSH], Small molecules, Adalimumab/administration, Biological Products/administration, Biological Products/adverse effects [MeSH], Remission Induction/methods [MeSH], Original Research, Ulcerative colitis, Gastrointestinal Agents/administration, Mirikizumab, Randomized Controlled Trials as Topic

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39404996
https://repository.publisso.de/resource/frl:6492869

Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2): 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)

Autori: Jonathan I. Silverberg Melinda J. Gooderham Amy S. Paller a ďalší

Zdroj: Am J Clin Dermatol
Silverberg, J I, Gooderham, M J, Paller, A S, Deleuran, M, Bunick, C G, Gold, L F S, Hijnen, D, Calimlim, B M, Lee, W-J, Teixeira, H D, Hu, X, Zhang, S, Yang, Y, Grada, A, Platt, A M & Thaçi, D 2024, 'Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis : 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)', American Journal of Clinical Dermatology, vol. 25, no. 3, pp. 485-496. https://doi.org/10.1007/s40257-024-00853-4

Predmety: Male, Adult, Adolescent, Severity of Illness Index, Dermatitis, Atopic, 12. Responsible consumption, Young Adult, Adolescent [MeSH], Double-Blind Method [MeSH], Female [MeSH], Adult [MeSH], Humans [MeSH], Dermatitis, Atopic/diagnosis [MeSH], Severity of Illness Index [MeSH], Treatment Outcome [MeSH], Janus Kinase Inhibitors/administration, Janus Kinase Inhibitors/therapeutic use [MeSH], Middle Aged [MeSH], Pruritus/etiology [MeSH], Patient Reported Outcome Measures [MeSH], Heterocyclic Compounds, 3-Ring/therapeutic use [MeSH], Heterocyclic Compounds, 3-Ring/administration, Janus Kinase Inhibitors/adverse effects [MeSH], Male [MeSH], Pruritus/drug therapy [MeSH], Dermatitis, Atopic/complications [MeSH], Quality of Life [MeSH], Young Adult [MeSH], Original Research Article, Dermatitis, Atopic/drug therapy [MeSH], Pruritus/diagnosis [MeSH], SDG 3 - Good Health and Well-being, Double-Blind Method, Dermatitis, Atopic/drug therapy, Humans, Janus Kinase Inhibitors, Patient Reported Outcome Measures, Janus Kinase Inhibitors/administration & dosage, 2. Zero hunger, Pruritus, Heterocyclic Compounds, 3-Ring/administration & dosage, Middle Aged, 3. Good health, Treatment Outcome, Quality of Life, Pruritus/drug therapy, Female, Heterocyclic Compounds, 3-Ring

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38528257
https://pure.eur.nl/en/publications/e9c71047-5a41-42b2-bd4f-02c8f8c139c8
https://doi.org/10.1007/s40257-024-00853-4
https://repository.publisso.de/resource/frl:6523882
https://pure.au.dk/portal/en/publications/377afe8a-7bde-4ff6-87e1-8380f922f180
https://doi.org/10.1007/s40257-024-00853-4

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis

Autori: Atul Deodhar Servet Akar Jeffrey R. Curtis a ďalší

Zdroj: Advances in Rheumatology, Vol 64, Iss 1, Pp 1-15 (2024)

Predmety: Janus kinase inhibitors/adverse effects, Spondylitis, Ankylosing, Tofacitinib, Diseases of the musculoskeletal system, RC925-935, Immunologic diseases. Allergy, RC581-607

Popis súboru: electronic resource

Relation: https://doaj.org/toc/2523-3106

Prístupová URL adresa: https://doaj.org/article/4a169e6a07ff48feabf7e83fe956d2f4

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

Autori: John Mascarenhas Marina Kremyanskaya Andrea Patriarca a ďalší

Zdroj: J Clin Oncol
Mascarenhas, J, Kremyanskaya, M, Patriarca, A, Palandri, F, Devos, T, Passamonti, F, Rampal, R K, Mead, A J, Hobbs, G, Scandura, J M, Talpaz, M, Granacher, N, Somervaille, T C P, Hoffman, R, Wondergem, M J, Salama, M E, Colak, G, Cui, J, Kiladjian, J-J, Vannucchi, A M, Verstovsek, S, Curto-García, N, Harrison, C & Gupta, V 2023, 'MANIFEST : Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 41, no. 32, pp. 4993-5004. https://doi.org/10.1200/JCO.22.01972
Mascarenhas, J, Kremyanskaya, M, Patriarca, A, Palandri, F, Devos, T, Passamonti, F, Rampal, R K, Mead, A J, Hobbs, G, Scandura, J M, Talpaz, M, Granacher, N, Somervaille, T C P, Hoffman, R, Wondergem, M J, Salama, M E, Colak, G, Cui, J, Kiladjian, J-J, Vannucchi, A M, Verstovsek, S, Curto-García, N, Harrison, C & Gupta, V 2023, 'Manifest : Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 41, no. 32, pp. 4993-5004. https://doi.org/10.1200/JCO.22.01972

Predmety: PHASE, DISCONTINUATION, Protein Kinase Inhibitors/adverse effects, Primary Myelofibrosis/drug therapy, Hemoglobins, 3211 Oncology and carcinogenesis, MOMELOTINIB, Janus Kinase Inhibitors/adverse effects, Nitriles, MANIFEST, Humans, Janus Kinase Inhibitors, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Protein Kinase Inhibitors, Aged, OUTCOMES, Janus Kinase 2/genetics, Science & Technology, Nitriles/therapeutic use, 1103 Clinical Sciences, ORIGINAL REPORTS, Hemoglobins/therapeutic use, Janus Kinase 2, EFFICACY, 3. Good health, Treatment Outcome, Oncology, Primary Myelofibrosis, SAFETY, TRIAL, Life Sciences & Biomedicine

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36881782
https://research.vumc.nl/en/publications/df08272b-5079-4509-8786-d08dbc3dbd1b
https://hdl.handle.net/2434/1000236
https://doi.org/10.1200/JCO.22.01972
https://www.mendeley.com/catalogue/8ccda1c7-4b7f-33ff-9e25-9d814acd3d8a/
https://doi.org/10.1200/JCO.22.01972
http://www.scopus.com/inward/record.url?scp=85159629620&partnerID=8YFLogxK
https://research.manchester.ac.uk/en/publications/5057a770-bdcc-4db8-88d9-a3ea3ecfd454
https://hdl.handle.net/2158/1308696
https://doi.org/10.1200/JCO.22.01972

Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study

Autori: Rasmus Westermann René Lindholm Cordtz Kirsten Duch a ďalší

Zdroj: Westermann, R, Cordtz, R, Duch, K, Mellemkjaer, L, Hetland, M L, Burden, A M & Dreyer, L 2022, 'Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study', Klinisk Kvalitetskonference 2022, Aalborg, Denmark, 29/11/2022-30/11/2022.
Westermann, R, Cordtz, R L, Duch, K, Mellemkjaer, L, Hetland, M L, Burden, A M & Dreyer, L 2022, 'Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study', Klinisk Kvalitetskonference 2022, Aalborg, Denmark, 29/11/2022-30/11/2022.
Westermann, R, Cordtz, R L, Duch, K, Mellemkjaer, L, Hetland, M L, Burden, A M & Dreyer, L 2024, 'Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study', Rheumatology, vol. 63, no. 1, kead163, pp. 93-102. https://doi.org/10.1093/rheumatology/kead163
Westermann, R, Cordtz, R, Duch, K, Mellemkjaer, L, Hetland, M L, Burden, A M & Dreyer, L 2022, ' Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study ', Klinisk Kvalitetskonference 2022, Aalborg, Denmark, 29/11/2022-30/11/2022 .
Westermann, R, Cordtz, R L, Duch, K, Mellemkjaer, L, Hetland, M L, Burden, A M & Dreyer, L 2022, ' Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study ', Klinisk Kvalitetskonference 2022, Aalborg, Denmark, 29/11/2022-30/11/2022 .

Predmety: Janus kinase inhibitors, Denmark, Antirheumatic Agents/adverse effects, Denmark/epidemiology, 3. Good health, Neoplasms/drug therapy, Cohort Studies, Arthritis, Rheumatoid, Arthritis, Rheumatoid/drug therapy, Antirheumatic Agents, Neoplasms, Janus Kinase Inhibitors/adverse effects, cancer, Humans, Janus Kinase Inhibitors, biologics, real-world evidence, RA, malignancy

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/37052534
https://vbn.aau.dk/da/publications/4be2dbe0-2d3c-4a93-b96b-786afbb35b13
https://vbn.aau.dk/da/publications/163b9e4d-f834-4c22-8055-98f4f14dec1e

A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo

Autori: Grossmann, Meghan C. Haidari, Wasim Feldman, Steven R.

Zdroj: Journal of Drugs in Dermatology. 22:664-667

Predmety: Nitriles/therapeutic use, Pyrimidines, Treatment Outcome, Pyrazoles/adverse effects, Janus Kinase Inhibitors/adverse effects, Nitriles, Vitiligo, Pyrimidines/therapeutic use, Humans, Pyrazoles, Janus Kinase Inhibitors, Vitiligo/drug therapy, 3. Good health

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/37410047
https://portal.findresearcher.sdu.dk/da/publications/24eb3cb8-32b2-412c-b970-e4e3ace3f579
https://doi.org/10.36849/JDD.7268

Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk

Autori: Sendaydiego, Xavier Gold, Laura Dubreuil, Maureen a ďalší

Prispievatelia: Sendaydiego, Xavier Gold, Laura Dubreuil, Maureen a ďalší

Zdroj: EISSN: 2574-3805 ; JAMA Network Open ; https://hal.science/hal-05029312 ; JAMA Network Open, 2024, 7 (11), pp.e2446336. ⟨10.1001/jamanetworkopen.2024.46336⟩

Predmety: MESH: Adolescent, MESH: Adult, MESH: Janus Kinase Inhibitors / adverse effects, MESH: Janus Kinase Inhibitors / therapeutic use, MESH: Male, MESH: Middle Aged, MESH: Neoplasms* / drug therapy, MESH: Neoplasms* / epidemiology, MESH: Piperidines / adverse effects, MESH: Piperidines / therapeutic use, MESH: Pyrimidines, MESH: Retrospective Studies, MESH: Antirheumatic Agents* / adverse effects, MESH: Tumor Necrosis Factor Inhibitors / adverse effects, MESH: Tumor Necrosis Factor Inhibitors / therapeutic use, MESH: United States / epidemiology, MESH: Young Adult, MESH: Antirheumatic Agents* / therapeutic use, MESH: Arthritis, Rheumatoid* / drug therapy, Rheumatoid* / epidemiology, MESH: Biological Products / adverse effects, MESH: Biological Products / therapeutic use, MESH: Female, MESH: Humans, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology

Relation: info:eu-repo/semantics/altIdentifier/pmid/39565623; PUBMED: 39565623; PUBMEDCENTRAL: PMC11579790

Dostupnosť: https://hal.science/hal-05029312
https://hal.science/hal-05029312v1/document
https://hal.science/hal-05029312v1/file/sendaydiego_2024_oi_241317_1731448377.52154.pdf
https://doi.org/10.1001/jamanetworkopen.2024.46336

Unsachgemäße Systemtherapie bei schwerer atopischer Dermatitis – fatale Langzeitschäden

Autori: Abeck, F. Booken, N. Schneider, S.

Zdroj: Dermatologie (Heidelb)

Predmety: Kasuistiken, Atopische Dermatitis, Oral glucocorticoids, Adult [MeSH], Humans [MeSH], Janus Kinase Inhibitors/adverse effects [MeSH], Adverse events, Atopic dermatitis, Systemic therapy, Systemtherapie, Nebenwirkungen, Orale Glukokortikosteroide, Dermatitis, Atopic/drug therapy [MeSH], 0211 other engineering and technologies, 0202 electrical engineering, electronic engineering, information engineering, 02 engineering and technology

Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00105-021-04922-1.pdf
https://repository.publisso.de/resource/frl:6448379

Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis / Januskinaser/signal transducer and activator of transcription-inhibition er en ny behandlingsmulighed ved reumatoid artritis

Autori: Fröling, Malte Mikkelsen, Clara Eggertsen, Peter Preben a ďalší

Zdroj: Ugeskrift for Laeger. 179(4):339

Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome.

Autori: Volpi, S. Insalaco, A. Caorsi, R. a ďalší

Predmety: Child, Preschool, Female, Humans, Interferon Type I/blood, Janus Kinase Inhibitors/adverse effects, Janus Kinase Inhibitors/therapeutic use, Lung Diseases, Interstitial/blood, Interstitial/drug therapy, Interstitial/genetics, Membrane Proteins/genetics, Off-Label Use, Pyrazoles/adverse effects, Pyrazoles/therapeutic use, Receptor, Interferon alpha-beta/antagonists & inhibitors, Skin Diseases/blood, Skin Diseases/drug therapy, Skin Diseases/genetics, Syndrome, Treatment Outcome, Vascular Diseases/blood, Vascular Diseases/drug therapy, Vascular Diseases/genetics, JAK inhibitor, Recurrent fever, pulmonary fibrosis

Popis súboru: application/pdf

Relation: Journal of Clinical Immunology; https://iris.unil.ch/handle/iris/72507; serval:BIB_399FE048032A; 000474418200004

Dostupnosť: https://iris.unil.ch/handle/iris/72507
https://doi.org/10.1007/s10875-019-00645-0